[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-433413-105":59,"doc-detail-433413-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancing-treatment-paradigms-the-role-of-psilocybin-in-managing-major-depressive-disorder","Advancing treatment paradigms - the role of psilocybin in managing major depressive disorder","","Psilocybin, a naturally occurring psychedelic compound, is being investigated as a novel therapeutic option for major depressive disorder (MDD), especially when standard approaches fail. The study evaluates psilocybin’s therapeutic potential by assessing efficacy, safety, and mechanisms of action, while also addressing societal and regulatory barriers. Clinical evidence from 2014–2024 indicates psilocybin targets serotonin 5-HT2A receptors, promoting neuroplasticity and brain connectivity for rapid, sustained symptom relief.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancing-treatment-paradigms-the-role-of-psilocybin-in-managing-major-depressive-disorder/433413/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancing-treatment-paradigms-the-role-of-psilocybin-in-managing-major-depressive-disorder/433413.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of evaluating psilocybin for major depressive disorder?","Question",{"text":112,"@type":113},"To assess psilocybin’s therapeutic potential by examining its efficacy, safety, and mechanisms of action, while also considering societal and regulatory challenges.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does psilocybin appear to relieve depressive symptoms according to the provided studies?",{"text":117,"@type":113},"Evidence indicates it acts on serotonin 5-HT2A receptors, enhancing neuroplasticity and brain connectivity to produce rapid and sustained symptom relief.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is psilocybin research and clinical use still limited?",{"text":121,"@type":113},"Its classification as a Schedule I substance in many countries and associated legal prohibitions and societal stigma restrict broader study and application.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},433413,1791420423,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nAdvancing treatment paradigms: the role of psilocybin in managing major depressive disorder  \nSana Rasheed, MBBSa , Rida Arif, MBBSa , Ahmed Asad Raza, MBBSa , Abedin Samadi, MBBSb ,*  \nAbstract  \nPsilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin’s therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory challenges that hinder its broader application. Key objectives include understanding how psilocybin alleviates depressive symptoms, investigating its neurobiological effects, and identifying gaps in current research.  \nThe methodology involved analyzing clinical studies conducted between 2014 and 2024, focusing on psilocybin as an intervention, either independently or in conjunction with psychotherapy. Evidence from these studies demonstrates that psilocybin acts on serotonin 5-HT2A receptors, enhancing neuroplasticity and brain connectivity to yield rapid and sustained symptom relief. Despite these promising findings, the use and study of psilocybin remains restricted due to its classification as a Schedule I substance in many countries. Legal prohibitions and societal stigma have significantly delayed progress in exploring psilocybin’s therapeutic applications.  \nThe findings highlight psilocybin’s potential to transform MDD treatment paradigms but emphasize the need to overcome regulatory barriers, conduct larger and more diverse studies, and establish long-term safety and efficacy data. Addressing these challenges is critical for integrating psilocybin into mainstream mental health care and unlocking its full therapeutic potential. Keywords: clinical trials, major depressive disorder, policy reform, psilocybin, psychedelic therapy  \nIntroduction  \nBackground on major depressive disorder  \nMajor depressive disorder (MDD) is a chronic mental health condition affecting over 280 million people globally. It disrupts mood, cognition, and behavior, elicits changes in sleep and appetite, and is accompanied by persistent sadness, loss of interest, and fatigue. MDD often worsens over time and is a leading cause of suicide, with high rates of recurrence. It is associated with medical conditions such as obesity, diabetes, stroke, Parkinson’s disease, and multiple sclerosis, and increases the risk of Alzheimer’s disease and sudden cardiac death. Its prevalence rose by 18% from 2005 to 2015, with women being twice as likely as men to be affected, particularly during puberty, peripartum periods, and menopause[1] . Approximately 13.3%  \naDepartment of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan and bDepartment of Medicine, Kabul University of Medical Science, Kabul, Afghanistan Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n*Corresponding author. Address: Department of Medicine, Kabul University of Medical Science, AtaTurk Avenue, Jamal Mena, 3rd District, Kabul 1004, Afghanistan. Tel.: +93 [77 668 9973. E-mail: abedin.samadi2019@gmail.com](77 668 9973. E-mail: abedin.samadi2019@gmail.com)[ ](77 668 9973. E-mail: abedin.samadi2019@gmail.com)(A. Samadi).  \nCopyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons AttributionNoDerivatives License 4.0, which allows for redistribution, commercial and noncommercial, as longas it is passed along unchanged and in whole, with credit to the author.  \nAnnals of Medicine & Surgery (2026) 88:478–486  \nReceived 26 August 2024; Accepted 5 November 2025  \nPublished online 25 November 2025  \n[http://dx.doi.org/10.1097/MS9.0000000000004349](http://dx.doi.org/10.1097/MS9.0000000000004349)  \nHIGHLIGHTS  \n● Psilocybin shows promise for treating MDD unresponsive ","cbCaivhV41hS85Yz","https://ap.wps.com/l/cbCaivhV41hS85Yz","pdf",1396672,"English","# Abstract\n# Introduction\n## Background on major depressive disorder\n## Current treatment approaches for MDD\n# Highlights","[{\"question\":\"What is the main goal of evaluating psilocybin for major depressive disorder?\",\"answer\":\"To assess psilocybin’s therapeutic potential by examining its efficacy, safety, and mechanisms of action, while also considering societal and regulatory challenges.\"},{\"question\":\"How does psilocybin appear to relieve depressive symptoms according to the provided studies?\",\"answer\":\"Evidence indicates it acts on serotonin 5-HT2A receptors, enhancing neuroplasticity and brain connectivity to produce rapid and sustained symptom relief.\"},{\"question\":\"Why is psilocybin research and clinical use still limited?\",\"answer\":\"Its classification as a Schedule I substance in many countries and associated legal prohibitions and societal stigma restrict broader study and application.\"}]","Advancing treatment paradigms - the role of psilocybin in managing major depressive disorder | PDF",1790664036,23]